Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17709147 | 0.80 | CYP19A1 (0.60) | CYP19A1KDM4EKMT2AALDH1A1GAA | |
| SCHEMBL619734 | 0.77 | MAPT (0.44) | KDM4EMEN1MAPTKMT2ATSHR | |
| SCHEMBL17709043 | 0.76 | CYP19A1 (0.47) | CYP19A1KDM4EKMT2ACNR2GPR55 | |
| SCHEMBL17709041 | 0.76 | CYP19A1 (0.47) | CYP19A1KDM4EKMT2ACNR2GPR55 | |
| SCHEMBL4352829 | 0.76 | MAPT (0.44) | KDM4EMEN1MAPTKMT2ATSHR | |
| SCHEMBL17709092 | 0.76 | CFTR (0.59) | — | |
| SCHEMBL17709110 | 0.73 | MAPT (0.42) | CYP19A1KDM4EMEN1MAPTKMT2A | |
| SCHEMBL17709203 | 0.71 | IDO1 (0.47) | IDO1MEN1KMT2ACNR2 | |
| SCHEMBL22446358 | 0.69 | KMT2A (0.49) | CYP19A1IDO1KMT2ATRPM8TRPV1 | |
| SCHEMBL3578838 | 0.68 | MAPT (0.47) | CYP19A1KDM4EMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212189-B1 | SUBSTITUTED CHROMANES AND METHOD OF USE | ABBVIE OVERSEAS SÀ RL (LU) | 2020-09-09 | — | — | EP | disclosed |
| US-20190127356-A1 | Substituted Chromanes and Method of Use | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2019-05-02 | — | — | US | disclosed |
| EP-3212189-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | AbbVie S.À.R.L. (LU) | 2017-09-06 | — | — | EP | disclosed |
| US-20170190693-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | ABBVIE S À R L (LU) | 2017-07-06 | — | — | US | disclosed |
| US-9642831-B2 | Substituted chromanes and method of use | ABBVIE S.Á.R.L. (LU) | 2017-05-09 | — | — | US | disclosed |
| WO-2016069757-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | ABBVIE INC. (US) | 2016-05-06 | — | — | WO | disclosed |
| US-20160120841-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | ABBVIE GLOBAL LIMITED (BM) | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190693-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | CFTR, CHRM3, CHRM2 | CYP19A1 994/4885IDO1 4103/4885KDM4E 4039/4885 |
| US-20160120841-A1 | SUBSTITUTED CHROMANES AND METHOD OF USE | CFTR, CHRM3, CHRM2 | CYP19A1 994/4885IDO1 4103/4885KDM4E 4039/4885 |
| US-20190127356-A1 | Substituted Chromanes and Method of Use | CFTR, CHRM3, CHRM2 | CYP19A1 994/4885IDO1 4103/4885KDM4E 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.